Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment

Fig. 5

Modulatory effects of regorafenib and lenvatinib on the HCC TME. Regorafenib was shown to revert M2 to M1 polarization, activate TANs, and inhibit EMT, while its effect on activating NK cells required more evidence. Lenvatinib decreased the population of TAMs in HCC while increasing the populations of NK, and cytotoxic T cells

Back to article page